• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Integer Announces CEO Succession Plan

    4/24/25 8:01:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ITGR alert in real time by email

    ~ Joseph Dziedzic to retire as President and CEO ~

    ~ Payman Khales appointed President and CEO effective October 24, 2025 ~

    PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization, today announced that Joseph Dziedzic will retire as President and Chief Executive Officer and will step down from the Board of Directors, effective October 24, 2025. At that time, Payman Khales, Chief Operating Officer, will assume the President and CEO position and join the Company's Board. To ensure a smooth transition, Mr. Dziedzic will serve as an advisor to the Company through March 31, 2026.

    "We are incredibly grateful to Joe, whose vision, strategy, and ability to create a high-performance culture has driven Integer's significant growth and value creation during his eight-year tenure as CEO," said Pamela G. Bailey, Chair of the Board. "Among many other accomplishments, Joe reshaped Integer's business to focus on high growth markets that address unmet patient needs, accelerated organic and inorganic investment in differentiated technologies, and developed and implemented the Integer Production System to create consistency across our manufacturing operations. Integer is delivering on its financial objectives of above market organic sales growth with expanding margins and is well positioned to continue this growth trajectory. We wish him the very best in a well-deserved retirement."

    "It has been an honor to lead the Integer team through this pivotal period in our Company's history, and I am proud of what we have accomplished for our customers and patients around the world," said Mr. Dziedzic. "Payman is the natural choice to guide Integer through our next chapter of growth. He is an exceptional leader who embodies our commitment to innovation, quality and operational excellence, and his track record speaks for itself. Payman has been an integral part of the development and execution of our strategy, both within Cardio & Vascular and across the enterprise, while leading Integer's Customer Operational Strategic Imperatives. I look forward to the Company's continued success under Payman's leadership."

    Mr. Khales joined Integer in 2018 as President of the Cardio & Vascular business. Under his leadership, the business established a successful market/customer-based strategy, doubling sales in seven years, accelerating market penetration, and achieving above-market growth, while improving service levels and profitability. Since becoming COO, he has overseen both of Integer's business units, Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation, along with global operations and manufacturing strategy.

    "I am honored to be named the next CEO of Integer and would like to thank Joe and the Board of Directors for having faith in me to lead this amazing company in its next chapter," said Mr. Khales. "I am excited about the strong momentum in our business as we continue to build differentiated capabilities and collaborate closely with our customers to deliver innovative medical device technologies to patients around the globe. I thank Joe for his mentorship over the past seven years and continued support in the coming months as we prepare to transition. He set the vision and strategy that transformed Integer into the strong company it is today, and I wish him a very enjoyable retirement later this year."

    First Quarter 2025 Results

    In a separate press release issued today, Integer reported first quarter 2025 financial results. The Company will host a conference call today at 8 a.m. CT / 9 a.m. ET to discuss these results.

    That press release, along with other investor materials, including a slide presentation and reconciliations of certain non-GAAP measures to their nearest GAAP measures, will also be available on investor.integer.net.

    About Payman Khales

    Mr. Khales currently serves as COO of Integer, and previously served as President of the Cardio & Vascular product category since 2018.

    Prior to joining Integer, Mr. Khales served as President of the Environmental Technologies business segment for CECO Environmental Corp., a diversified global provider of engineered technologies to the environmental, energy, and fluid handling and filtration industrial segments. He also held several progressive leadership roles at Ingersoll Rand Company.

    Mr. Khales holds an Executive Master of Business Administration from Indiana University's Kelley School of Business, and a Bachelor of Science in Mechanical Engineering from École Polytechnique de Montréal.

    About Integer®

    Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net.

    Investor Relations: Media Relations:
    Kristen StewartKelly Butler
    [email protected][email protected]
    551.337.3973469.731.6617


    Primary Logo

    Get the next $ITGR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ITGR

    DatePrice TargetRatingAnalyst
    5/22/2025$140.00Neutral → Buy
    Citigroup
    3/28/2025$145.00Outperform
    Raymond James
    2/21/2025Outperform → Perform
    Oppenheimer
    12/3/2024$160.00Overweight
    Wells Fargo
    7/16/2024$135.00Outperform
    Oppenheimer
    5/15/2024$137.00Buy
    Truist
    4/15/2024$105.00 → $135.00Neutral → Buy
    BofA Securities
    3/14/2024$137.00Buy
    CL King
    More analyst ratings

    $ITGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Dziedzic Joseph W converted options into 36,202 shares and covered exercise/tax liability with 13,395 shares, increasing direct ownership by 99% to 45,807 units (SEC Form 4)

      4 - Integer Holdings Corp (0001114483) (Issuer)

      6/13/25 6:09:03 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Maxwell Martin C sold $1,051,279 worth of shares (8,720 units at $120.56) and exercised 8,720 shares at a strike of $49.90 (SEC Form 4)

      4 - Integer Holdings Corp (0001114483) (Issuer)

      6/6/25 6:49:22 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Spence Donald J sold $1,774,340 worth of shares (14,739 units at $120.38) and exercised 14,739 shares at a strike of $19.43 (SEC Form 4)

      4 - Integer Holdings Corp (0001114483) (Issuer)

      6/6/25 6:09:27 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Integer Holdings upgraded by Citigroup with a new price target

      Citigroup upgraded Integer Holdings from Neutral to Buy and set a new price target of $140.00

      5/22/25 8:16:14 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Raymond James initiated coverage on Integer Holdings with a new price target

      Raymond James initiated coverage of Integer Holdings with a rating of Outperform and set a new price target of $145.00

      3/28/25 8:19:38 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings downgraded by Oppenheimer

      Oppenheimer downgraded Integer Holdings from Outperform to Perform

      2/21/25 6:56:47 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ITGR
    SEC Filings

    See more
    • Integer Holdings Corporation Announces Conversion Period for 2.125% Convertible Senior Notes due 2028

      PLANO, Texas, July 02, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) ("Integer" or the "Company"), a leading medical device contract development and manufacturing organization, today notified holders of its 2.125% Convertible Senior Notes due 2028 (the "Notes") that the Notes are convertible, at the option of the holders (the "Conversion Option") beginning on July 1, 2025, and ending at the close of business on September 30, 2025. The Notes are convertible into cash, up to the principal amount of the Notes, and in cash, shares of the Company's common stock or a combination thereof, at the Company's election, in respect of the remainder, if any, of the Company's conversi

      7/2/25 4:05:00 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Announces Conference Call to Discuss Second Quarter 2025 Results

      PLANO, Texas, June 26, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the second quarter ended June 27, 2025, on Thursday, July 24, 2025, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the second quarter on July 24 prior to the conference call. Conference call details: Date: Thursday, July 24, 2025Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 307-1963Conference ID: 31

      6/26/25 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer to Present at Truist Securities MedTech Conference on June 17

      PLANO, Texas, June 03, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization, today announced participation in the 2025 Truist Securities MedTech Conference, to be held June 17, 2025, in Boston. Members of the Integer executive leadership team will participate in a fireside chat on Tuesday, June 17, at 10:40 a.m. ET. A live webcast of the presentation will be accessible under "News & Events" on the Investor Relations section of the Integer website at investor.integer.net. Learn more about Integer at www.integer.net. About Integer®Integer Holdings Corporation (NYSE:ITGR) is one of the largest medica

      6/3/25 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Integer Holdings Corp (0001114483) (Filer)

      7/2/25 4:10:31 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Integer Holdings Corp (0001114483) (Filer)

      5/28/25 7:08:15 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SD filed by Integer Holdings Corporation

      SD - Integer Holdings Corp (0001114483) (Filer)

      5/23/25 4:08:47 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

      SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

      2/9/24 9:59:01 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

      SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

      1/30/24 1:15:44 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

      SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

      2/10/23 2:42:23 PM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Financials

    Live finance-specific insights

    See more
    • Integer Announces Conference Call to Discuss Second Quarter 2025 Results

      PLANO, Texas, June 26, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the second quarter ended June 27, 2025, on Thursday, July 24, 2025, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the second quarter on July 24 prior to the conference call. Conference call details: Date: Thursday, July 24, 2025Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 307-1963Conference ID: 31

      6/26/25 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Announces CEO Succession Plan

      ~ Joseph Dziedzic to retire as President and CEO ~~ Payman Khales appointed President and CEO effective October 24, 2025 ~ PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization, today announced that Joseph Dziedzic will retire as President and Chief Executive Officer and will step down from the Board of Directors, effective October 24, 2025. At that time, Payman Khales, Chief Operating Officer, will assume the President and CEO position and join the Company's Board. To ensure a smooth transition, Mr. Dziedzic will serve as an advisor to the Company through March 31, 2026. "We

      4/24/25 8:01:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Integer Holdings Corporation Reports First Quarter 2025 Results

      ~ Strong start to the year with 1Q25 financial results ~~ Reiterating 2025 sales and adjusted operating income outlook; raising adjusted EPS outlook ~ PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 28, 2025.   First Quarter 2025 Highlights (compared to First Quarter 2024, except as noted) Sales increased 7% to $437 million, with organic growth of 6%.GAAP operating income increased $11 million to $50 million, an increase of 28%. Non-GAAP adjusted operating income increased $9 million to $71 million, an increase of 14%.GAAP income (loss) from continuing operations decreased $43 million to a

      4/24/25 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ITGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Integer Announces Board Leadership Transition

      PLANO, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource (MDO) manufacturer, announced today that Bill R. Sanford will be retiring as Chair of the Integer Board of Directors at the conclusion of the Company's 2022 annual meeting of stockholders, which is scheduled to be held on May 18, 2022. Commensurate with this carefully planned transition, the Board of Directors plans to appoint current long-standing Integer Board member Pamela G. Bailey to serve as the next Chair of the Board. "On behalf of the Integer Board of Directors, I wish to thank Bill for his immense contribution and insightful leadership over the past 22 ye

      3/17/22 8:00:00 AM ET
      $ITGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care